ArticlePhysiological research2025
Combined RAS Modulation: The Effect on Plasma and Tissue Angiotensin Peptide Levels.
Article in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined renin-angiotensin system (RAS) inhibition can enhance blood pressure control but has not improved clinical outcomes, underscoring the importance of complex changes in angiotensin peptide profiles in combined RAS blockade. We investigated hemodynamics and circulating and tissue angiotensin peptide profile in spontaneously hypertensive rats (SHR) treated with lisinopril, olmesartan and aliskiren and their dual combinations. SHR exhibited hypertension and left ventricular hypertrophy along with reduced circulating Ang I, Ang II, and Ang 1-7. Lisinopril produced the most pronounced antihypertensive effects, with additional reduction when combined with olmesartan or aliskiren. In contrast, aliskiren - either alone or in combination - had only modest effects in this low-RAS setting. The morphological changes of the myocardium largely mirrored the blood pressure responses across treatment groups, reinforcing the hemodynamic basis of structural remodeling in SHR. Lisinopril and olmesartan markedly increased Ang I and Ang 1-7, but lisinopril suppressed Ang II while olmesartan increased Ang II. Aliskiren further reduced Ang II and Ang 1-7. Across treatment strategies, dual RAS blockade frequently decreased both renal and circulating Ang 1-7 despite greater hemodynamic efficacy. Tissue analyses revealed minimal intrinsic Ang II synthesis in the left ventricle, consistent with AT?-dependent uptake of circulating Ang II, while renal peptide profiles indicated some local enzymatic activity with differential reliance on ACE and neprilysin. Our results advocate a cautious, mechanism-aware approach to combination RAS blockade and support therapeutic strategies that balance blood pressure lowering with preservation of the Ang 1-7 axis.
Indexed as
Identifiers
41532628PMC12849780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.